Allogeneic stem cell transplantation as treatment for myelofibrosis.
about
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosisOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation-association with chronic GVHD in late-onset adult patients.
P2860
Allogeneic stem cell transplantation as treatment for myelofibrosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Allogeneic stem cell transplantation as treatment for myelofibrosis.
@ast
Allogeneic stem cell transplantation as treatment for myelofibrosis.
@en
type
label
Allogeneic stem cell transplantation as treatment for myelofibrosis.
@ast
Allogeneic stem cell transplantation as treatment for myelofibrosis.
@en
prefLabel
Allogeneic stem cell transplantation as treatment for myelofibrosis.
@ast
Allogeneic stem cell transplantation as treatment for myelofibrosis.
@en
P2093
P2860
P356
P1476
Allogeneic stem cell transplantation as treatment for myelofibrosis.
@en
P2093
Castleton A
Kottaridis PD
Papageorgiou SG
P2860
P2888
P304
P356
10.1038/SJ.BMT.1705516
P407
P577
2006-10-02T00:00:00Z